Larimar Therapeutics
LRMR
136 hedge funds and large institutions have $275M invested in Larimar Therapeutics in 2025 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 61 increasing their positions, 26 reducing their positions, and 9 closing their positions.
968% more call options, than puts
Call options by funds: $22.7M | Put options by funds: $2.13M
222% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 9
135% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 26
53% more capital invested
Capital invested by funds: $180M → $275M (+$94.7M)
17% more funds holding
Funds holding: 116 → 136 (+20)
2.58% more ownership
Funds ownership: 97.32% → 99.89% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$35.2M |
| 2 |
RI
RTW Investments
New York
|
+$11.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.12M |
| 4 |
Goldman Sachs
New York
|
+$5.41M |
| 5 |
Millennium Management
New York
|
+$4.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$3.35M |
| 2 |
Two Sigma Investments
New York
|
-$2.88M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.46M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.23M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$888K |
LRMR Hedge Fund Activity: Q3 2025 in Review
136 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2025, worth a combined $275M — up 53% from $180M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new LRMR positions and 9 closed out — a net gain of 20 holders — while 61 added to existing stakes and 26 trimmed.
The largest buyer was Deerfield Management, adding an estimated $35.2M. The largest seller was Two Sigma Advisers, cutting an estimated $3.35M.
- 136 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2025, up from 116 in Q2 2025.
- Funds reported $275M of Larimar Therapeutics stock for Q3 2025, up 53% quarter-over-quarter.
- 29 funds opened new Larimar Therapeutics positions in Q3 2025 and 9 closed out, a net change of +20 holders.
- The largest Larimar Therapeutics buyer in Q3 2025 was Deerfield Management, an estimated $35.2M added.
- The largest Larimar Therapeutics seller in Q3 2025 was Two Sigma Advisers, an estimated $3.35M sold.
Based on aggregated 13F filings for Q3 2025.